Literature DB >> 16932630

Challenges of predicting treatment response in patients with rheumatoid arthritis.

Josef S Smolen1, Daniel Aletaha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16932630     DOI： 10.1038/ncprheum0050

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN： 1745-8382


× No keyword cloud information.
  9 in total

1.  Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial.

Authors:  Jeffrey R Curtis; Shuo Yang; Lang Chen; Grace S Park; Bojena Bitman; Brian Wang; Iris Navarro-Millan; Arthur Kavanaugh
Journal:  Ann Rheum Dis       Date:  2011-10-13       Impact factor: 19.103

2.  Yin-yang and Zheng: Exported from Chinese medicine.

Authors:  Hong-ji Zhang; Zhan-xiang Wang
Journal:  Chin J Integr Med       Date:  2014-04-03       Impact factor: 1.978

3.  Sub-typing of rheumatic diseases based on a systems diagnosis questionnaire.

Authors:  Herman A van Wietmarschen; Theo H Reijmers; Anita J van der Kooij; Jan Schroën; Heng Wei; Thomas Hankemeier; Jacqueline J Meulman; Jan van der Greef
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

4.  Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and metabolomics measurements.

Authors:  Herman A van Wietmarschen; Weidong Dai; Anita J van der Kooij; Theo H Reijmers; Yan Schroën; Mei Wang; Zhiliang Xu; Xinchang Wang; Hongwei Kong; Guowang Xu; Thomas Hankemeier; Jacqueline J Meulman; Jan van der Greef
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

5.  The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium.

Authors:  C A Wijbrandts; M G W Dijkgraaf; M C Kraan; M Vinkenoog; T J Smeets; H Dinant; K Vos; W F Lems; G J Wolbink; D Sijpkens; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2007-11-29       Impact factor: 19.103

6.  ¹H-NMR-Based Metabolomic Study for Identifying Serum Profiles Associated with the Response to Etanercept in Patients with Rheumatoid Arthritis.

Authors:  Roberta Priori; Luca Casadei; Mariacristina Valerio; Rossana Scrivo; Guido Valesini; Cesare Manetti
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

7.  Hypogalactosylation of immunoglobulin G in rheumatoid arthritis: relationship to HLA-DRB1 shared epitope, anticitrullinated protein antibodies, rheumatoid factor, and correlation with inflammatory activity.

Authors:  Christian Schwedler; Thomas Häupl; Ulrich Kalus; Véronique Blanchard; Gerd-Rüdiger Burmester; Denis Poddubnyy; Berthold Hoppe
Journal:  Arthritis Res Ther       Date:  2018-03-14       Impact factor: 5.156

8.  Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis.

Authors:  Josef S Smolen; Jung-Yoon Choe; Michael E Weinblatt; Paul Emery; Edward Keystone; Mark C Genovese; Gihyun Myung; Evelyn Hong; Inyoung Baek; Jeehoon Ghil
Journal:  RMD Open       Date:  2020-01

9.  Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritis.

Authors:  Josef S Smolen; Young Mo Kang; Wan-Hee Yoo; Paul Emery; Michael E Weinblatt; Edward C Keystone; Mark C Genovese; Gihyun Myung; Inyoung Baek; Jeehoon Ghil
Journal:  Arthritis Res Ther       Date:  2020-08-14       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.